Search for a trial

A prospective, multicenter, randomised, double-blind, placebo-controlled,
parallel groups, phase 2/3 study to compare the efficacy and safety of
masitinib versus placebo in the treatment of patients suffering from
Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to compare the efficacy and the safety of an experimental drug, masitinib,in combination with riluzole to placebo in combination with riluzole administered during 48 weeks to patients suffering from ALS.You will be…

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with option for an additional two years of treatment

Primary objective:Evaluate the effect of two doses versus placebo gantenerumab subcutaneous injections on the change in Clinical Dementia Rating Sum of Boxes scale (CDR SOB), a global measure of cognition and functional capacitySecondary objectives:…

CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease

To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…

ASCENDING SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACO-DYNAMICS OF SRA-444 ADMINISTERED ORALLY TO HEALTHY ADULT SUBJECTS

Primary: to assess the safety and tolerability of ascending single oral doses of SRA-444 in healthy adult subjectsSecondary: to obtain preliminary PK and PD profiles of SRA-444 in healthy adult subjects to evaluate the effect of a high-fat meal on…

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI*N METHYL D ASPARTIC ACID RECEPTOR (NMDAR) OR ANTI*LEUCINE RICH GLIOMA INACTIVATED 1 (LGI1) ENCEPHALITIS

This study has been transitioned to CTIS with ID 2023-504226-18-00 check the CTIS register for the current data. This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in each of…

Ghrelin treatment of comatose patients after cardiac arrest:
A phase 2 clinical trial to estimate safety and efficacy of ghrelin to promote cerebral recovery

Primary objective: We aim to measure safety and efficacy of intravenous treatment with acyl-ghrelin to promote cerebral recovery in comatose patients after cardiac arrest. Safety will be monitored throughout hospitalization and during follow-up…